Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03238196
Title Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Vanderbilt-Ingram Cancer Center

breast carcinoma


Erdafitinib + Fulvestrant + Palbociclib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST